CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analog that functions as a potent stimulator of the GH/IGF-1 axis. Evidence from our corpus suggests its efficacy in achieving sustained hormonal elevation, with preclinical studies demonstrating its ability to restore normal growth in GHRH-deficient models. Tesamorelin, also a GHRH analog, has shown efficacy in managing HIV-associated lipodystrophy by improving body composition, specifically reducing visceral fat and hepatic fat. Studies also suggest Tesamorelin may improve neurocognitive function in HIV patients with abdominal obesity. Both peptides are subject to anti-doping scrutiny due to their potential as performance-enhancing drugs.
| CJC-1295 | Tesamorelin | |
|---|---|---|
| Drug class | ghrh analog | ghrh analog |
| Studies in corpus | 25 | 39 |
| Highest evidence tier | rct | meta analysis |
| Evidence tier mix | in vitro · 6 preclinical animal · 2 rct · 2 other · 13 review · 1 | case report · 1 other · 11 cohort · 2 rct · 12 preclinical animal · 2 review · 3 meta analysis · 1 in vitro · 2 |
| Studies with explicit sample size | 0 | 1 |
| Head-to-head studies in corpus | 3 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real CJC-1295 and Tesamorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 746 CJC-1295 batches across 335 manufacturers, 97.33% avg purity.
We tested 2386 Tesamorelin batches across 1024 manufacturers, 98.94% avg purity.
We hold deeper lab coverage on Tesamorelin (2386 batches tested). Tesamorelin edges ahead on average measured purity (97.33% vs 98.94%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both CJC-1295 and Tesamorelin — the gold-standard direct comparison evidence.
This highly sensitive and robust nano LC-Q/Orbitrap MS method represents a significant advancement in the detection of GHRH and its analogs, which are frequently abused performance-enhancing drugs. The enhanced sensitivity and specificity will greatly impro…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown metabolites, it provides WADA-accredited l…
This review highlights a critical distinction for peptide users and clinicians: only GLP-1R agonists currently possess reproducible, high-quality evidence for a specific musculoskeletal indication (knee osteoarthritis symptom relief). For other widely promo…
No direct head-to-head trials in our corpus. Indirect comparison only. While both CJC-1295 and Tesamorelin are GHRH analogs, their primary clinical applications, based on the studies indexed here, appear to diverge. CJC-1295 is highlighted for its long-acting properties and its ability to provide sustained elevation of GH/IGF-1, with preclinical studies showing its potential for treating growth hormone deficiency. One study on CJC-1295 for HIV-associated visceral obesity was terminated early, leaving its efficacy in that specific indication unconfirmed. Tesamorelin, on the other hand, has more robust evidence in our corpus specifically for the treatment of HIV-associated lipodystrophy, demonstrating improvements in body composition, visceral fat reduction, and potential neurocognitive benefits. Reviews in our corpus indicate that both peptides, along with others, currently lack robust human orthopaedic evidence for routine use. Detection methods for both peptides as prohibited substances in sports are also a focus of research.
Looking for vendor-level purity, endotoxin, and HPLC data on CJC-1295 or Tesamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.